Latest News & Features
Americas
Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed. 25 October 2017
Americas
Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications. 24 October 2017
Americas
Nearly 80 members of the House of Representatives have written to the heads of three government departments to voice concerns over regulatory proposals in the biotechnology and gene-editing fields. 24 October 2017
Americas
The Saint Regis Mohawk Tribe, the owner of dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), has hit back at Mylan for questioning its sovereign immunity. 24 October 2017
Big Pharma
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the
developing challenges facing patentability in the life sciences field. 24 October 2017
Americas
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados. 24 October 2017
Big Pharma
The EU General Court has affirmed a decision that a trademark application for ‘SeboCalm’ is confusingly similar to the earlier word mark ‘Sebotherm’. 23 October 2017
Americas
A San Diego-based company has announced plans to sell a generic version of Allergan’s dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), just days after four patents covering the drug were invalidated. 23 October 2017
Big Pharma
Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics. 20 October 2017
Big Pharma
Europe’s highest court has found that in parallel lawsuits dealing with an identical trademark, the first court must take priority over the second—but not in all cases. 19 October 2017